These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

269 related items for PubMed ID: 24152622

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Prediction of macrometastasis in axillary lymph nodes of patients with invasive breast cancer and the utility of the SUV lymph node/tumor ratio using FDG-PET/CT.
    Futamura M, Asano T, Kobayashi K, Morimitsu K, Nawa M, Kanematsu M, Morikawa A, Mori R, Yoshida K.
    World J Surg Oncol; 2015 Feb 14; 13():49. PubMed ID: 25885028
    [Abstract] [Full Text] [Related]

  • 3. Factors affecting the accuracy of 18F-FDG PET/CT in evaluating axillary metastases in invasive breast cancer.
    Kutluturk K, Simsek A, Comak A, Gonultas F, Unal B, Kekilli E.
    Niger J Clin Pract; 2019 Jan 14; 22(1):63-68. PubMed ID: 30666022
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. The value of dual-time-point 18F-FDG PET/CT for identifying axillary lymph node metastasis in breast cancer patients.
    Choi WH, Yoo IR, O JH, Kim SH, Chung SK.
    Br J Radiol; 2011 Jul 14; 84(1003):593-9. PubMed ID: 21081574
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of lymph node status after neoadjuvant chemotherapy in breast cancer patients: comparison of diagnostic performance of ultrasound, MRI and ¹⁸F-FDG PET/CT.
    You S, Kang DK, Jung YS, An YS, Jeon GS, Kim TH.
    Br J Radiol; 2015 Aug 14; 88(1052):20150143. PubMed ID: 26110204
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of the Usefulness of FDG-PET/CT for Nodal Staging of Breast Cancer.
    Orsaria P, Chiaravalloti A, Caredda E, Marchese PV, Titka B, Anemona L, Portarena I, Schillaci O, Petrella G, Palombi L, Buonomo OC.
    Anticancer Res; 2018 Dec 14; 38(12):6639-6652. PubMed ID: 30504372
    [Abstract] [Full Text] [Related]

  • 10. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ.
    Breast Cancer; 2013 Apr 14; 20(2):167-73. PubMed ID: 22311581
    [Abstract] [Full Text] [Related]

  • 11. The value of the SUV ratio between lymph node and bone marrow in predicting pelvic lymphatic metastasis of patients with locally advanced cervical cancer: an integrated PET/CT study.
    Liu Y, Hua J, Liu L, Zhang W, Xu S, Chen X.
    Nucl Med Commun; 2022 Nov 01; 43(11):1155-1160. PubMed ID: 36003034
    [Abstract] [Full Text] [Related]

  • 12. Prediction of Advanced Axillary Lymph Node Metastases (ypN2-3) Using Breast MR imaging and PET/CT after Neoadjuvant Chemotherapy in Invasive Ductal Carcinoma Patients.
    Kim WH, Lee SW, Kim HJ, Chae YS, Jeong SY, Jung JH, Park HY, Lee WK.
    Sci Rep; 2018 Feb 16; 8(1):3181. PubMed ID: 29453385
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Preoperative Prediction of Cervical Lymph Node Metastasis Using Primary Tumor SUVmax on 18F-FDG PET/CT in Patients with Papillary Thyroid Carcinoma.
    Jung JH, Kim CY, Son SH, Kim DH, Jeong SY, Lee SW, Lee J, Ahn BC.
    PLoS One; 2015 Feb 16; 10(12):e0144152. PubMed ID: 26636824
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Comparison of 68Ga-DOTANOC and 18F-FDG PET-CT Scans in the Evaluation of Primary Tumors and Lymph Node Metastasis in Patients With Rectal Neuroendocrine Tumors.
    Zhou Z, Wang Z, Zhang B, Wu Y, Li G, Wang Z.
    Front Endocrinol (Lausanne); 2021 Feb 16; 12():727327. PubMed ID: 34539577
    [Abstract] [Full Text] [Related]

  • 18. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J, Wang Y, Mo M, Bao X, Zhang Y, Liu G, Zhang J, Geng D.
    Oncotarget; 2015 Oct 06; 6(30):29388-95. PubMed ID: 26336821
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.